XBRL Rendering Preview
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2019
May 13, 2019
Document and Entity Information:    
Registrant Name ACQUIRED SALES CORP.  
Registrant CIK 0001391135  
SEC Form 10-Q  
Period End date Mar. 31, 2019  
Fiscal Year End --12-31  
Trading Symbol aqsp  
Tax Identification Number (TIN) 870479286  
Number of common stock shares outstanding   2,579,648
Filer Category Non-accelerated Filer  
Entity's Reporting Status Current Yes  
Entity Small Business true  
Emerging Growth Company false  
Ex Transition Period false  
Amendment Flag false  
Document Fiscal Year Focus 2019  
Document Fiscal Period Focus Q1  
Entity Incorporation, State Country Name Nevada  
Entity Address, Address Line One 31 N. Suffolk Lane, Lake Forest, Illinois  
Entity Address, Postal Zip Code 60045  
CONDENSED BALANCE SHEETS (Unaudited) - USD ($)
Mar. 31, 2019
Dec. 31, 2018
Current Assets    
Cash and Cash Equivalents $ 2,796,915 $ 0
Total Current Assets 2,796,915 0
Total Assets 2,796,915 0
Accounts Payable - Related Party    
Accounts Payable - Related Party - Payable to William C. Jacobs 136,825 164,417
Accounts Payable - Related Party - Payable to Gerard M. Jacobs 3,555 24,583
Accounts Payable - Related Party - Payable to Other Related Party 0 4,000
Accounts Payable - Related Party 140,380 193,000
Trade Accounts Payable 20,722 113,450
Notes Payable - Payable to Joshua A. Bloom 0 20,025
Notes Payable - Payable to Gerard M. Jacobs 0 10,766
Notes Payable - Related Party 0 30,791
Interest - Payable to Joshua A. Bloom 0 914
Interest - Payable to Gerard M. Jacobs 0 467
Interest Payable - Related Party 0 1,381
Series A Convertible Preferred Stock Dividends Payable 18,552 0
Total Current Liabilities 179,654 338,622
Commitments and Contingencies 0 0
Shareholders' Equity    
Preferred stock 30 0
Common Stock, $0.001 par value; 100,000,000 shares authorized; 2,579,648 and 2,369,648 shares outstanding at March 31, 2019 and December 31, 2018, respectively 2,580 2,370
Additional paid-in capital 16,683,332 13,664,697
Accumulated Deficit (14,068,681) (14,005,689)
Total Shareholders' Equity (Deficit) 2,617,261 (338,622)
Total Liabilities and Shareholders' Equity $ 2,796,915 $ 0
CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares
Mar. 31, 2019
Dec. 31, 2018
Preferred Stock, par or stated value $ 0.001 $ 0.001
Preferred Stock, shares authorized 10,000,000 10,000,000
Common Stock, par or stated value $ 0.001 $ 0.001
Common Stock, shares authorized 100,000,000 100,000,000
Common Stock, shares outstanding 2,579,648 2,369,648
Series A Convertible Preferred Stock    
Preferred Stock, par or stated value $ 0.001 $ 0.001
Preferred Stock, shares authorized 400,000 400,000
Preferred Stock, shares issued 29,900 0
CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Income Statement [Abstract]    
Selling, General and Administrative Expense $ (26,473) $ (16,995)
Professional Fees (21,467) (3,073)
Interest Expense (27,998) 0
Loss From Operations (75,938) (20,068)
Other Income    
Interest Income 2,302 0
Gain on Settlement 29,196 0
Total Other Income 31,498 0
Loss Before Provision for Income Taxes (44,440) (20,068)
Provision for Income Taxes 0 0
Net Loss $ (44,440) $ (20,068)
Basic and Diluted Earnings Loss per Share $ (0.02) $ (0.01)
Basic and diluted weighted average number of common shares outstanding: 2,405,777 2,369,648
CONDENSED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Stockholders' Equity Attributable to Parent, Beginning Balance at Dec. 31, 2017 $ 2,370 $ 13,554,524 $ (13,785,068) $ (228,174)
Shares, Outstanding, Beginning Balance at Dec. 31, 2017 2,369,648      
Net Loss   (20,068) (20,068)
Stockholders' Equity Attributable to Parent, Ending Balance at Mar. 31, 2018 $ 2,370 13,554,524 (13,805,136) (248,242)
Shares, Outstanding, Ending Balance at Mar. 31, 2018 2,369,648      
Stockholders' Equity Attributable to Parent, Beginning Balance at Dec. 31, 2018 $ 2,370 13,664,697 (14,005,689) (338,622)
Shares, Outstanding, Beginning Balance at Dec. 31, 2018 2,369,648      
Exercise of rights to purchase warrants to purchase shares of common stock, Amount   $ 210 1,892   2,102
Exercise of rights to purchase warrants to purchase shares of common stock, Shares   210,000      
Issuance of warrants to purchase common stock     26,773   26,773
Issuance of Series A Convertible Preferred Stock for cash, Amount $ 30   2,989,970   2,990,000
Issuance of Series A Convertible Preferred Stock for cash, Shares 29,900        
Series A Preferred Stock dividend payable       (18,552) (18,552)
Net Loss     (44,440) (44,440)
Stockholders' Equity Attributable to Parent, Ending Balance at Mar. 31, 2019 $ 30 $ 2,580 $ 16,683,332 $ (14,068,681) $ 2,617,261
Shares, Outstanding, Ending Balance at Mar. 31, 2019 29,900 2,579,648      
CONDENSED STATEMENT OF CASH FLOWS (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Cash Flows From Operating Activities    
Net Loss $ (44,440) $ (20,068)
Adjustments to Reconcile Loss to Net Cash Used in Operating Activities:    
Financing Cost - Issuance of Warrants to Purchase Common Stock 26,773 0
Changes in Operating Assets and Liabilities:    
Accounts Payable to Related Parties (51,396) 16,995
Trade Accounts Payable (92,728) 3,073
Net Cash Used in Operating Activities (161,791) 0
Cash Flows From Financing Activities    
Financing Cost - Proceeds From Borrowing Under Notes Payable to Related Parties 14,772 0
Financing Cost - Repayment of Borrowings Under Notes Payable to Related Parties (45,562) 0
Financing Cost - Repayment of Interest Payable to Related Parties (2,606) 0
Exercise of Rights to Purchase Warrants to Purchase Shares of Common Stock 2,102 0
Issuance of Series A Convertible Preferred Stock 2,990,000 0
Net Cash Provided by Financing Activities 2,958,706 0
Net Increase in Cash 2,796,915 0
Cash and Cash Equivalents at Beginning of Year 0 0
Cash and Cash Equivalents at End of Year 2,796,915 0
Supplemental Cash Flow Information    
Cash paid for interest 2,606 0
Cash paid for income taxes $ 0 $ 0
Note 1 - Description Of The Business Of Acquired Sales Corp.
3 Months Ended
Mar. 31, 2019
Accounting Policies [Abstract]  
Note 1 - Description Of The Business Of Acquired Sales Corp.

NOTE 1 – DESCRIPTION OF THE BUSINESS OF ACQUIRED SALES CORP.

 

Acquired Sales Corp. (hereinafter sometimes referred to as “Acquired Sales”, the “Company”, “AQSP”, “Acquired”, the “Company”, “we”, “us”, “our”, etc.) was organized under the laws of the State of Nevada on January 2, 1986. The Company does not currently have any business or any sources of revenue.

 

The Company wants to acquire all or a portion of one or more operating businesses.

 

Management of the Company currently is exclusively exploring potential acquisitions of all or a portion of one or more operating businesses involving the manufacture and sale of cannabidiol (CBD)-infused products such as beverages, muscle/joint rubs, oils, crystals, tinctures, bath bombs, isolate, relief balms, elixirs, body washes, med sticks, lotions, vape pens and cartridges, shatter, and gummies (a “CBD-Infused Products Company”).

 

In order to consummate a particular acquisition of a CBD-Infused Products Company, management of the Company is open-minded to the concept of also acquiring all or a portion of one or more operating businesses and/or assets that are related to such CBD-Infused Products Company, for example operating businesses and/or assets involving distilled spirits, beer, wine, hemp, paraphernalia, cannabis, tetrahydrocannabinol (THC)-infused products, and real estate. 

 

Signing of Letter of Intent to Acquire 100% of the Ownership Interests of CBD Lion LLC

 

On May 8, 2019, Acquired Sales Corp. (the “Company”), Gerard M. Jacobs (“GJacobs”) and William C. “Jake” Jacobs (“WJacobs”) entered into a Letter of Intent with CBD Lion LLC (“Lion”) and its owners (the “Lion Owners”) to, subject to a number of conditions, acquire 100% of the ownership of Lion (the “Transaction”). The consideration to be paid by the Company in the proposed acquisition of Lion is: two million dollars ($2,000,000) in cash, plus unregistered common stock of the Company (the "Stock Consideration") in an amount that is the greater of: (i) five million (5,000,000) shares or (ii) a number of shares with a value at closing of the Transaction, based on the Company’s share price, equal to 50% of the value of the aggregate consideration deemed paid to the Lion Owners for their ownership interests in Lion, which could hypothetically increase the Stock Consideration to a number significantly higher than five million (5,000,000). The Lion Owners shall have "piggyback registration rights" for the common stock shares underlying the Stock Consideration and "demand registration rights" that are triggered if no registration statement covering the Stock Consideration is filed with the U.S. Securities and Exchange Commission within 120 days following the closing of the Transaction. In addition, the Letter of Intent requires that at the closing of the Transaction, the Company shall cause up to four hundred sixty-two thousand four hundred thirty dollars ($462,430) of related party debt owed by Lion to be repaid in full. 

 

The terms of the proposed Transaction must be set forth in a definitive agreement. There are no assurances that the Company will be successful in negotiating an acceptable definitive agreement, when or whether a definitive agreement will be reached between the parties, or that the proposed Transaction will be consummated. Even if a definitive agreement is executed, the terms of the proposed Transaction may change materially from the terms set forth in the Letter of Intent. There will be many conditions to closing of the Transaction, many of which are outside of the parties’ control and we cannot predict whether these conditions will be satisfied. There are no assurances when or if closing of the Transaction will occur, even if the parties successfully negotiate and sign a definitive agreement.

 

Closing of the acquisition of Lion is subject to a number of conditions, including but not limited to the completion of due diligence investigation of Lion by the Company that is acceptable to the Company, completion of a capital raise by the Company of at least $4 million, completion of an audit of Lion acceptable to the Company, execution of definitive acquisition documents, execution of employment agreements with certain key Lion executives, obtaining necessary third-party approvals, including a tax opinion to be provided by Lion’s tax counsel indicating that the proposed Transaction will qualify as a tax-free reorganization, and completion of all necessary securities filings. In the event that most of the foregoing conditions are met, as detailed in the Letter of Intent, prior to the closing of the proposed Transaction, the Company will make a $300,000 loan to Lion to be used by Lion exclusively for growth capital.

 

The Company is currently engaged in due diligence of Lion and has not yet started to negotiate a definitive agreement for the proposed Transaction. The Letter of Intent will terminate if (i) no audit of Lion satisfactory to the Company has been delivered by August 31, 2019; the Company fails to raise $4 million by September 30, 2019; or (iii) the proposed Transaction has not closed by October 31, 2019.

 

The Letter of Intent contains customary provisions prohibiting Lion from soliciting or encouraging any other acquisition proposal or entering into any negotiations or agreements for an alternative acquisition or financing transaction prior to the termination of the Letter of Intent.

 

In the event that the proposed acquisition of Lion is completed, the Letter of Intent requires that as soon as practicable following the closing of the proposed sale, the Company will change its name to "CBD Lion Corp.” and request a new trading symbol that better relates to the new proposed name.

 

Stock Sale and Purchase Agreement - Ablis Holding Company

 

Ablis Holding Company ("Ablis") is a rapidly growing leader in the exciting CBD-infused beverage industry. Ablis' all-natural, shelf-stable, GMO-free, non-alcoholic, lemon ginger, cranberry blood orange, and 0 calorie lemon water beverages target the mainstream health market and contain no THC. Ablis also manufactures and sells CBD-infused rubs, oils and crystals. Ablis' beverages are now being distributed in 11 states, online throughout the country, Puerto Rico and Guam. Also, Silver Moon Brewing, a brewery in Bend, has recently begun producing and selling Hazibliss, Oregon’s first hemp CBD-infused draft beer that incorporates Ablis’ cranberry blood orange CBD beverage.

 

On April 30, 2019, the Company, GJacobs, and WJacobs entered into a Stock Sale and Purchase Agreement with Ablis, Ablis, Inc., and James A. Bendis (“Bendis”) wherein the Company paid $399,200 for a post transaction 4.99% ownership of Ablis' equity. Ablis is in the business of manufacturing and sale of CBD-infused beverages, and CBD-infused products. The Stock Sale and Purchase Agreement requires that Ablis use a portion of the purchase proceeds to pay off at least $381,000 of its liabilities. Another portion of the purchase proceeds will make capital available for expanded off-line and online advertising, and additional staff and equipment.

 

The Stock Sale and Purchase Agreement also sets out terms for an additional equity purchase of Ablis such that the Company may purchase up to an additional 15% of Ablis for $1,200,000 so that the Company would then own 19.99% of the ownership equity of Ablis. The Company desires to purchase up to an additional 15% of the common stock of Ablis, but doing so will only be possible if the Company closes on the sale of additional Series A Convertible Preferred Stock ("Preferred Stock") or otherwise raises capital.

 

The management team of Ablis will continue to lead Ablis. The terms of the Stock Sale and Purchase Agreement entitle GJacobs to be a member of the board of directors of Ablis, entitles WJacobs, to be provided with access to Ablis' financial information, grants WJacobs, financial oversight functions over Ablis, and allows WJacobs the right to provide consulting/advisory services to Ablis. WJacobs’ reasonable expenses will be covered by Ablis. The Stock Sale and Purchase Agreement also requires that GJacobs and WJacobs be introduced to the owners of Ablis’ CBD isolate suppliers, and any other companies in the hemp, CBD and cannabis industries with whom Ablis and/or Bendis have relationships, and whom may potentially be interested in entering into a stock sale or merger with the Company.

 

The Stock Sale and Purchase Agreement requires that Ablis evaluate and seriously consider a sale of Ablis or taking Ablis public within 60 months from April 30, 2019 and that it use commercially reasonable best efforts, to close a mutually acceptable alternative exit opportunity for the Company within 72 months from April 30, 2019.

 

The Company’s investment in Ablis made the Company a minority owner of Ablis. As a minority owner, the Company will not be able to recognize any portion of Ablis’ revenues or earnings in the Company’s financial statements. The Company may, at some point, receive commissions for helping to sell Ablis' products either online or offline. The Company’s investment in Ablis will be tested for potential impairment of value on a quarterly basis.

 

Stock Purchase Agreement - Bendistillery Inc. and Bend Spirits, Inc.

 

Founded in 1996, Bendistillery Inc. ("Bendistillery") is an award-winning craft distillery, with an outstanding reputation for producing Crater Lake Spirits brands including vodkas, gins, whiskeys, and white label brands offered through Bend Spirits, Inc. ("Bend Spirits").

 

On April 30, 2019, the Company, GJacobs, and WJacobs entered into a Stock Purchase Agreement with Bendistillery, Bend Spirits, Bendis Homes Pinehurst, LLC, an Oregon limited liability company (“Landowner”), Bendis, and Alan T. Dietrich (“Dietrich”) wherein the Company paid $1,347,300 for a post transaction 4.99% ownership of Bendistillery’s equity and $149,700 for a post transaction 4.99% ownership of Bend Spirits’ equity. Bendistillery and Bend Spirits are in the business of manufacturing and sale of alcoholic beverages, and the manufacturing of CBD-infused beverages and CBD-infused products. The Stock Purchase Agreement requires that Bendistillery and Bend Spirits use a portion of the purchase proceeds to pay off at least $835,000 of their collective liabilities. Another portion of the purchase proceeds will make capital available for expanded off-line and online advertising, and additional staff and equipment.

 

The Stock Purchase Agreement also sets out terms for an additional equity purchase of Bendistillery such that the Company may purchase up to an additional 15% of Bendistillery for $4,050,000 so that the Company would then own 19.99% of the ownership equity of Bendistillery. Per the terms of the Stock Purchase Agreement, the Company may also purchase up to an additional 15% of Bend Spirits for $450,000 such that the Company would then own 19.99% of the ownership equity of Bend Spirits. The Company desires to purchase up to an additional 15% of the common stock of each of Bendistillery and Bend Spirits under the Stock Purchase Agreement, but doing so will only be possible if the Company closes on the sale of additional Preferred Stock or otherwise raises capital, and receives approval to do so from the Oregon Liquor Control Commission.

 

Pursuant to the Stock Purchase Agreement, Landowner (as landlord) and Bendistillery (as tenant) have entered into a long-term lease of the 23 acres in Tumalo outside Bend, Oregon, where Bendistillery and Bend Spirits conduct their businesses (the “Real Estate”), which lease (the “Lease”) is consistent with the following terms: the initial term of the Lease is 20 years at a rent of $17,500 per month; Tenant has the right, in its sole discretion, to exercise a series of options to extend the term of the Lease up to a maximum of 99 years; and Tenant has a 60-day right of first refusal if Landowner ever decides to sell all or any portion of the Real Estate. Bendis is the owner of Landowner.

 

The management teams of Bendistillery and Bend Spirits will continue to lead their respective companies. The terms of the Stock Purchase Agreement entitle GJacobs to be a member of the board of directors of Bendistillery and Bend Spirits, entitle WJacobs to be provided with access to financial information, grants WJacobs financial oversight functions over Bendistillery and Bend Spirits, and allows WJacobs the right to provide consulting/advisory services to Bendistillery and Bend Spirits. WJacobs’ reasonable expenses will be covered by Bendistillery and Bend Spirits, as well as an advisory fee of not less than $5,000 per quarter. The Stock Purchase Agreement also requires that GJacobs and WJacobs be introduced to the owners of Deschutes Brewery, Silver Moon Brewing, LBD Beverage, and any other companies in the distilled spirits, beer, wine, hemp, CBD and cannabis industries with whom Bendistillery, Bend Spirits, Bendis and/or Dietrich have relationships, and whom may potentially be interested in entering into a stock sale or merger with the Company.

 

The Stock Purchase Agreement requires that Bendistillery and Bend Spirits evaluate and seriously consider a sale of Bendistillery and Bend Spirits or taking them public within 60 months from April 30, 2019 and that they use commercially reasonable best efforts to close a mutually acceptable alternative exit opportunity for the Company within 72 months from April 30, 2019.

 

The Company’s investments in Bendistillery and Bend Spirits made the Company a minority owner of these companies. As a minority owner, the Company will not be able to recognize any portion of Bendistillery’s or Bend Spirits’ revenues or earnings in the Company’s financial statements. The Company may, at some point, receive commissions for helping sell Bendistillery’s products either online or offline. The Company’s investments in Bendistillery and Bend Spirits will be tested for potential impairment in value on a quarterly basis.

 

Acceptance of Subscriptions From Accredited Investors to Purchase Newly Issued Series A Convertible Preferred Stock

 

Between February 27, 2019 and May 13, 2019, the Company accepted subscriptions from accredited investors to purchase 66,150 shares of newly issued Preferred Stock for an aggregate purchase price of $6,615,000 in cash. These 66,150 shares of Preferred Stock are convertible at the option of the holders into 6,615,000 shares of newly issued common stock of the Company, or $1.00 per share of common stock of the Company. The Company has committed to file a registration statement covering the shares of newly issued common stock of the Company into which the Preferred Stock can be converted (the "Registration Statement"). The Preferred Stock will receive an annual dividend, and will be subject to mandatory conversion, under terms and conditions set forth in the Certificate of Designation of the Preferred Stock.

 

Acquisition Process

 

The structure of the Company’s participation in business opportunities and ventures will continue to be situational. The Company is likely to structure future acquisitions as a purchase of 19.99% or less, or 50.01% or more, of a target company’s equity ownership interest, or as a so-called tax-free reorganization. It is likely that the anticipated value of the business and/or securities that the Company acquires relative to the current value of the Company’s securities will result in the issuance of a relatively large number of newly issued shares of the Company, and, as a result, substantial additional dilution to the percentage ownership of our current stockholders. Moreover, the Company’s present management and shareholders may not have control of a majority of our voting shares following a merger or purchase of stock. It is possible that the shareholders of the acquired entity or the persons who provide the capital to the Company to finance a merger or purchase of stock will gain control of the Company’s voting stock and the Company’s directors may resign and new directors may be appointed without any vote by the shareholders. Those directors are entitled to replace the Company’s officers without stockholder vote.

 

In regard to nearly all of the Company’s potential acquisitions, the Company is typically focused upon acquiring 19.99% or less, or 50.01% or more, of existing privately held businesses whose owners are willing to consider selling a percentage of the equity ownership interest of their businesses, or merging their entire businesses into the Company or a wholly-owned subsidiary of the Company in a so-called tax-free reorganization, and whose management teams are enthusiastic about continuing to operate their businesses following the transactions with the Company.

 

Closing such purchases of stock or so-called tax-free reorganizations will likely require the Company to raise millions of dollars of capital, in order to pay the cash portion of the transaction consideration. The Company can provide no assurance or guaranty whatsoever that it will be able to raise such millions of dollars of capital on acceptable terms and conditions, if at all.

 

An Investment Committee appointed by the Company’s Board of Directors, currently consisting of GJacobs, director Thomas W. Hines, CPA CFA, and WJacobs, CPA, will review material furnished to it and will vote whether or not the Investment Committee believes a potential acquisition is in the Company’s best interests and the interests of the Company’s shareholders. If the Investment Committee votes unanimously to approve a potential acquisition, then such acquisition will be presented to the Board of Directors of the Company for their review and a vote. The Company does not intend to proceed forward with a potential acquisition without the unanimous approval of the Investment Committee and approval by a majority of the Company’s Board of Directors.

 

The Company intends to source acquisition opportunities through its CEO and directors and their contacts, and in some cases through finders. These contacts include the shareholders of Ablis, professional advisors such as attorneys and accountants, securities broker dealers, venture capitalists, members of the financial community, other businesses and others who may present solicited and unsolicited proposals. Management believes that business opportunities may become available to us due to a number of factors, including, among others: (1) The Company’s ownership of shares in one or more CBD-Infused Products Companies; (2) management’s historical experience building large public companies; (3) management’s contacts and acquaintances; and (4) the Company’s flexibility with respect to the manner in which the Company may be able to structure, finance, merge with or acquire any business opportunity.

 

The analysis of new business opportunities will be undertaken by or under the supervision of the Investment Committee appointed by our Board of Directors. Inasmuch as the Company will have limited funds available to search for business opportunities, the Company will not be able to expend significant funds on a complete and exhaustive investigation of such business or opportunity. The Company will, however, investigate, to the extent believed reasonable by the Investment Committee, such potential business opportunities by conducting a so-called “due diligence investigation”.

 

In a due diligence investigation, the Company intends to obtain and review materials regarding the business opportunity. Typically, such materials will include information regarding a target business’ products, services, contracts, management, ownership, and financial information. In addition, the Company intends to cause the Investment Committee to meet personally with management and key personnel of target businesses, ask questions regarding the target businesses’ prospects, tour facilities,

and conduct other reasonable investigation of the target businesses to the extent of the Company’s limited financial resources and management and technical expertise.

 

There is no guarantee that the Company can obtain or maintain the funding needed for its operations, including the funds necessary to search for and investigate acquisition candidates, and to close an acquisition including paying the substantial costs of legal, accounting and other relevant professional services.

 

As of May 13, 2019, the Company has cash on hand of approximately $4,379,077, which are proceeds from the sale of Preferred Stock between February 27, 2019 and May 13, 2019. In prior years, the Company’s payables have been greater than their cash on hand. The Company has inconsistent income generating ability and is therefore reliant on raising money from loans or stock sales.

Note 2 - Basis of Presentation and Significant Accounting Policies
3 Months Ended
Mar. 31, 2019
Disclosure Text Block [Abstract]  
Note 2 - Basis of Presentation and Significant Accounting Policies

NOTE 2 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation The accompanying financial statements include the accounts and operations of the Company for all periods presented.

 

Condensed Financial Statements – The accompanying financial statements are condensed and do not include all disclosures normally required by generally accepted accounting principles. These statements should be read in conjunction with the annual financial statements included in Form 10-K filed with the U.S. Securities and Exchange Commission on March 13, 2019. In particular, the basis of presentation and significant accounting principles were presented in Note 1 to the annual financial statements. In the opinion of management, all adjustments necessary for a fair presentation have been included in the accompanying unaudited condensed financial statements and consist of only normal recurring adjustments, except as disclosed herein. The results of operations for the three months ended March 31, 2019 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2019.

 

Use of Estimates – The preparation of financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) typically requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management’s estimates and assumptions. In the past, significant estimates included share-based compensation forfeiture rates and the potential outcome of future tax consequences of events that have been recognized for financial reporting purposes. Actual results and outcomes may differ from our estimates and assumptions.

 

Basic and Diluted Earnings (Loss) Per Common Share – Basic earnings (loss) per common share is determined by dividing earnings (loss) by the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per common share is calculated by dividing earnings (loss) by the weighted-average number of common shares and dilutive common share equivalents outstanding during the period. When dilutive, the incremental potential common shares issuable upon exercise of stock options and warrants are determined by the treasury stock method. The following table summarizes the calculations of basic and diluted earnings (loss) per common share for the three months ended March 31, 2019 and 2018:

 

    For the Three Months Ended
    March 31,
    2019   2018
Net Loss   $ (44,440)     $ (20,068)  
Weighted Average Shares Outstanding   2,405,777      2,369,648   
         
Basic and Diluted Loss per Share   $ (0.02)     $ (0.01)  

 

At March 31, 2019, there were outstanding options to purchase 1,186,132 shares of common stock exercisable at between $0.001 and $3.18 per share, (b) rights to purchase warrants to purchase 2,740,000 shares of common stock exercisable at between $0.01 and $1.85 per share, and (c) financing warrants to purchase 56,250 shares of common stock exercisable at $0.03 per share. As of the date of this report, none of these outstanding options, rights to purchase warrants or financing warrants have been exercised into shares of common stock. However, all of them may be exercised at any time in the sole discretion of the holder except for certain rights to purchase warrants to purchase 1.25 million shares of our commons stock, which are not exercisable until a performance contingency is met. Also outstanding at March 31, 2019 were 29,900 shares of Preferred Stock, convertible into 2,990,000 shares of the Company’s common stock at an exercise price of $1.00 per common stock share pursuant to the Series A Preferred Stock’s voluntary conversion rights. All of these options, rights to purchase warrants to purchase shares of common stock, financing warrants and Preferred Stock shares were excluded from the computation of diluted earnings (loss) per share because their effect would be anti-dilutive.

 

In comparison, at March 31, 2018, there were 1,358,774 stock options and rights to purchase warrants to purchase 2,700,000 shares of the Company’s common stock outstanding that were excluded from the computation of diluted earnings (loss) per share because their effects would have been anti-dilutive.

 

Recent Accounting Pronouncements – The Company is unaware of any new accounting pronouncements that will impact the Company upon adoption, and the Company has not recently adopted any new accounting standards.

Note 3 - Risks and Uncertainties
3 Months Ended
Mar. 31, 2019
Disclosure Text Block [Abstract]  
Note 3 - Risks and Uncertainties

NOTE 3 – RISKS AND UNCERTAINTIES

 

Going Concern – The Company has a history of recurring losses which have resulted in an accumulated deficit of $14,068,681 as of March 31, 2019. During the three months ended March 31, 2019, the Company recognized a net loss of $44,440.

Also, the Company has Preferred Stock outstanding that is currently accruing dividends at the rate of 3% per year. We have no income to pay these dividends. The Company does not have any business or any sources of revenue to pay these dividends or our other operating expenses. As a result, there is substantial doubt that the Company will be able to continue as a going concern. Bankruptcy of the Company at some point in the future is a possibility. The accompanying financial statements do not include any

adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classificiation of liabilities that might be necessary should the Company be unable ot continue as a going concern.

The Company currently has no revenue-generating subsidiaries. Management plans to sustain the Company as a going concern by taking the following actions: (1) acquiring and/or developing profitable businesses that will create positive income from operations; and/or (2) completing private placements of the Company’s common stock and/or preferred stock. Management believes that by taking these actions, the Company will be provided with sufficient future operations and cash flow to continue as a going concern. However, there can be no assurances or guarantees whatsoever that the Company will be successful in consummating such actions on acceptable terms, if at all. Moreover, any such actions can be expected to result in substantial dilution to the existing shareholders of the Company.

 

The Company’s investments in Ablis, Bendistillery and Bend Spirits made the Company a minority owner of these companies. As a minority owner, the Company will not be able to recognize any portion of Ablis’, Bendistillery’s or Bend Spirits’ revenues or earnings in the Company’s financial statements. The Company may, at some point, receive commissions for helping sell Ablis' and Bendistillery's online or offline. The Company’s investments in Ablis, Bendistillery and Bend Spirits will be tested for potential impairment of value on a quarterly basis.

Note 4 - Notes Receivable
3 Months Ended
Mar. 31, 2019
Disclosure Text Block [Abstract]  
Note 4 - Notes Receivable

NOTE 4 – NOTES RECEIVABLE

 

The William Noyes Webster Foundation, Inc.

 

The Foundation, a non-profit Massachusetts corporation, has received a provisional registration from the Commonwealth of Massachusetts to own and operate a medical marijuana cultivation facility in Plymouth, Massachusetts, and a medical marijuana dispensary in Dennis, Massachusetts. Jane W. Heatley (“Heatley”) is the founder and a member of the board of directors of the Foundation.

 

Teaming Agreement – The Company believes it is highly likely that the board of directors of the Foundation will only approve contracts that have been negotiated and approved by Heatley. Consequently, on July 8, 2014, the Company entered into a Teaming Agreement (the "Teaming Agreement") with Heatley, in which, among other things: (1) the Company and Heatley agreed to use their respective best efforts, working exclusively together as a team, and not as a partnership or other entity, in order to consummate transactions, agreements, contracts or other arrangements pursuant to which the Company will provide capital and expertise to the Foundation; and (2) Heatley agreed that Heatley shall not, and shall not permit the Foundation to, discuss or negotiate for debt or equity financing, or consulting services or other expertise, from any third party. The Company claims that Heatley violated the Teaming Agreement by discussing and negotiating for debt or equity financing, or consulting services or other expertise, from at least one third party. Heatley claims that the Company violated the Teaming Agreement alleging that the Company failed to lend funds to the Foundation in accordance with the Teaming Agreement. The Company believes Heatley's claim to be baseless. No assurances whatsoever can be made that Heatley will comply with the terms of the Teaming Agreement, nor that the Company will be able to adequately enforce the terms of the Teaming Agreement if it is ever the subject of litigation.

 

Promissory Note – On July 14, 2014, the Foundation signed and delivered to the Company a Secured Promissory Note (the "Note") which is in the stated loan amount of $1,500,000, and is secured by a Security Agreement of even date therewith (the “Security Agreement”). The Note provides that the $1,500,000 loan may be advanced in one or more installments as the Foundation and the Company may mutually agree upon. The Foundation and the Company mutually agreed that the first installment of this loan would be $602,500. Pursuant to instructions from the Foundation, on July 14, 2014, the Company paid $2,500 owed by the Foundation to one of its consultants, and the Company advanced $600,000 directly to the Foundation. The amount and timing of subsequent loan installments under the Note, which could have totaled $897,500, had not yet been mutually agreed upon between the Foundation and the Company as of the date of the Note.

 

Between April and July 2015, the Company loaned an additional $135,350 to the Foundation, evidenced by the Note and secured by the Security Agreement. Following such additional loans, the principal of the loan from the Company to the Foundation, evidenced by the Note and secured by the Security Agreement, is now $737,850. The principal balance outstanding under the Note bore interest at the rate of 12.5% per annum, compounded monthly. It was contemplated that the first payment of accrued interest by the Foundation under the Note would be made as soon after the Foundation commences operations of the Plymouth Cultivation Facility and the Dennis Dispensary as the Foundation's cash flows shall reasonably permit, but in any event no later than one year after the Foundation commences operations. The principal of the Note would be payable in eight consecutive equal quarterly installments, commencing on the last day of the calendar quarter in which the Foundation commences operations. Principal on the Note and related accrued interest would be considered past due if the aforementioned payments were not received by their due dates.

 

Uncollectable Note and Interest Receivable – The Company assessed the collectability of the Note based on the adequacy of the Foundation’s collateral and the Foundation’s capability of repaying the Note according to its terms. Based on this assessment, on September 1, 2015, the Company concluded that Note and interest receivable would not be collectible. As such, the Company wrote off the Note totaling $737,850 and interest receivable totaling $97,427 as bad debt expense on September 1, 2015.

Note 5 - Amounts Owed to Related Parties
3 Months Ended
Mar. 31, 2019
Related Party Transactions [Abstract]  
Note 5 - Amounts Owed to Related Parties

NOTE 5 – AMOUNTS OWED TO RELATED PARTIES AND THIRD PARTIES

 

Amounts Owed to Related Parties

 

At March 31, 2019, there are expense reimbursements owed to the Company's CEO GJacobs, CEO totaling $3,555. In comparison, at December 31, 2018, there were expense reimbursements owed to GJacobs totaling $24,583.

 

On June 21, 2016, a company affiliated with GJacobs, made a non-interest-bearing loan of $4,000 to the Company, which was payable upon demand. The $4,000 note payable to the company affiliated with GJacobs was repaid during the quarter ended March 31, 2019.

 

At March 31, 2019, there are independent contractor fees of $130,000, salary of $5,000, and expense reimbursements of $1,825 owed to WJacobs, who is now the Company's President and CFO, totaling $136,825. In comparison, at December 31, 2018, there were independent contractor fees of $160,000 and expense reimbursements of $4,417 owed to WJacobs totaling $164,417. WJacobs is the son of GJacobs, our Chief Executive Officer, and the nephew of director James S. Jacobs.

 

During the quarter ended March 31, 2019, WJacobs was paid $40,000 for independent contractor fees he was owed for May 2016 through December 2016. He was also reimbursed $4,417 for expenses he incurred from January 2016 through November 2018.

 

Financing Warrants – On July 13, 2018, the Audit Committee, Compensation Committee, and full Board of Directors of the Company approved by unanimous written consent borrowings by the Company on the following terms:(1) proceeds of the borrowings will be used to pay professional fees owed to our outside auditors, our stock transfer agent, and our securities counsel, and to pay other obligations of the Company; (2) the borrowings will be evidenced by promissory notes of the Company, accruing interest at the rate of 15% annually; (3) the notes will be jointly secured by a first lien security interest in all of the assets of the Company, pursuant to a security agreement signed by the Company in favor of the lenders, UCC filings in favor of the lenders, and a pledge to the lenders of the note payable by the William Noyes Webster Foundation Inc. to the Company; (4) the notes shall be due and payable upon demand by the lenders delivered to the Company; and (5) for each $1,000 loaned by the Company on these terms, the lender of such $1,000 shall receive warrants to purchase 1,250 shares of common stock of the Company, at an exercise price of $0.03 per share, exercisable at the discretion of such lender any time on or before July 16, 2023.

 

As of December 31, 2018, a total of $30,791 had been borrowed by the Company on such terms, and warrants to purchase 25,000 shares of common stock of the Company had been issued to director Joshua A. Bloom and warrants to purchase 12,500 shares of common stock of the Company had been issued to the Company's CEO GJacobs. As of December 31, 2018, there was also a total of $1,381 in interest payable to Joshua A. Bloom and GJacobs, related to these borrowings.

 

Between January 7, 2019 and February 6, 2019, an additional $14,772 was lent by GJacobs to the Company on such terms, and warrants to purchase 18,750 shares of common stock of the Company were issued to GJacobs.

 

On March 13, 2019, all of these borrowings and the related interest payable to Joshua A. Bloom and GJacobs was repaid. In total, $21,540 was paid to Joshua A. Bloom, and $26,628 was paid to GJacobs.

 

Amounts Owed to Third Parties

 

On March 15, 2019, the Company settled and paid its debt of $61,500 to its previous independent registered public accounting firm, Eide Bailly LLP.

Note 6 - Shareholders' Equity
3 Months Ended
Mar. 31, 2019
Disclosure Text Block [Abstract]  
Note 6 - Shareholders' Equity

NOTE 6 – SHAREHOLDERS’ EQUITY

 

Issuance of Preferred StockThe Company has authorized 400,000 shares of its Preferred Stock. Each share of Preferred Stock may be converted into 100 shares of common stock. The Preferred Stock pays dividends at the rate of 3% annually. The Preferred Stock dividends are cumulative if the Company does not have the necessary cash to pay the dividend when due. The Preferred Stock dividends shall cease to accrue at such time as the Company’s Common Stock has closed at $3.00 per share or higher for 20 consecutive trading days after the first date that the registration statement is effective, and there have been, on average, at least 25,000 shares traded on each of those 20 consecutive trading days. The Preferred Stock have no voting rights. The holders of the

 

Preferred Stock shall have voluntary conversion rights. Shares of Preferred Stock are subject to mandatory conversion (in the discretion of the Company) at such time as the Company’s common stock has closed at $5.00 per share or higher for 20 consecutive trading days after the first date that the registration statement is effective, and there have been, on average, at least 50,000 shares traded on each of those 20 consecutive trading days.   

 

Between February 27, 2019 and May 13, 2019, the Company accepted subscriptions from accredited investors to purchase 66,150 shares of newly issued Preferred Stock for an aggregate purchase price of $6,615,000 in cash. These 66,150 shares of Preferred Stock are convertible at the option of the holders into 6,615,000 shares of newly issued common stock of the Company, or $1.00 per share of common stock of the Company. The Company has committed to file a registration statement covering the shares of newly issued common stock of the Company into which the Preferred Stock can be converted (the "Registration Statement"). The Preferred Stock will receive an annual dividend, and will be subject to mandatory conversion, under terms and conditions set forth in the Certificate of Designation of the Preferred Stock.

 

Issuance of Financing Warrants – On July 13, 2018, the Audit Committee, Compensation Committee, and full Board of Directors of AQSP approved by unanimous written consent borrowings by AQSP on the following terms:(1) proceeds of the borrowings will be used to pay professional fees owed to our outside auditors, our stock transfer agent, and our securities counsel, and to pay other obligations of AQSP; (2) the borrowings will be evidenced by promissory notes of AQSP, accruing interest at the rate of 15% annually; (3) the notes will be jointly secured by a first lien security interest in all of the assets of AQSP, pursuant to a security agreement signed by AQSP in favor of the lenders, UCC filings in favor of the lenders, and a pledge to the lenders of the note payable by the William Noyes Webster Foundation Inc. to AQSP; (4) the notes shall be due and payable upon demand by the lenders delivered to AQSP; and (5) for each $1,000 loaned by AQSP on these terms, the lender of such $1,000 shall receive warrants to purchase 1,250 shares of common stock of AQSP, at an exercise price of $0.03 per share, exercisable at the discretion of such lender any time on or before July 16, 2023.

 

During the quarter ended March 31, 2019, a total of $14,772 was borrowed by AQSP on such terms from GJacobs, and warrants to purchase 18,750 shares of common stock of AQSP were issued to G Jacobs.

 

The warrants to purchase common stock that were issued to G Jacobs during the quarter ended March 31, 2019 were valued using the Black-Scholes valuation model as of the date they were issued. The values of these warrants were fully expensed because the notes are payable upon demand. The expense recognized related to the issuance of the warrants to GJacobs during the quarter ended March 31, 2019 was $26,773, which was a debit to interest expense and credit to additional paid-in capital.

 

Share-Based Compensation – There was no share-based compensation expense recognized during the periods ended March 31, 2019 or 2018.

 

Stock Option and Warrant Activity – The following is a summary of stock option and warrant activity as of March 31, 2019 and changes during the period then ended:

 

      Weighted-Average Aggregate
    Weighted-Average Remaining Contractual Intrinsic
  Shares Exercise Price (a) Term (Years) Value
Exercisable Options, Rights to Purchase Warrants to Purchase Common Stock and Financing Warrants Outstanding, December 31, 2018 2,923,632 $ 0.87    4.93    $ 2,410,100   
Financing Warrants Issued During the Period 18,750      
Rights to Purchase Warrants to Purchase Shares of Common Stock Exercised During Period (210,000)      
Exercisable Options, Rights to Purchase Warrants to Purchase Common Stock and Financing Warrants Outstanding, March 31, 2019 2,732,382 $ 0.93    4.20    $ 2,176,550   
Outstanding Options, Rights to Purchase Warrants to Purchase Common Stock and Financing Warrants, March 31, 2019 3,982,382 $ 1.22    4.65    $ 2,176,550   

Note 7 - Contingent Contractual Obligations and Commercial Commitments
3 Months Ended
Mar. 31, 2019
Disclosure Text Block [Abstract]  
Note 7 - Contingent Contractual Obligations and Commercial Commitments

NOTE 7 – CONTINGENT CONTRACTUAL OBLIGATIONS AND COMMERCIAL COMMITMENTS

 

Compensation to GJacobs

 

The Board of Directors of the Company has committed to pay compensation to GJacobs, our Chief Executive Officer, as an inducement to him to introduce attractive acquisitions to the Company. The amount of the authorized compensation is 10% of the consideration paid by the Company to acquire equity ownership interests in target companies. Notwithstanding the foregoing, the timing, amount and structure of GJacobs' compensation in regard to successful acquisitions of equity ownership interests in target companies is currently expected to be determined pursuant to negotiations to be held between GJacobs and director Joshua A. Bloom, the chairman of the Compensation Committee of the Company's Board of Directors.

 

Payment of Finders’ Fees Related to Ablis

 

The Company has agreed to pay finders’ fees to two finders in regard to the purchase of 4.99% of the stock of Ablis. Such finders’ fees are warrants to purchase a total of 14,042 unregistered shares of common stock of the Company at an exercise of $1 per share, exercisable at any time on or before April 30, 2024.

 

The Company has also agreed to pay those two finders additional warrants to purchase shares of common stock of the Company at an exercise price of $1 per share exercisable at any time on or before April 30, 2024; in the event that the Company closes on the purchase of up to an additional 15% of the common stock of Ablis, then the total amount of such warrants will be 2,814 unregistered shares of common stock of AQSP at an exercise price of $1 per share for each additional one percent of Ablis’ common stock so purchased (a maximum issuance of warrants to purchase 42,210 unregistered shares of common stock of the Company at an exercise price of $1 per share).

 

Payment of Finder’s Fee Related to CBD Lion

 

The Company has agreed to pay a finder’s fee to a finder if the Company closes on the acquisition of 100% of the ownership interests of CBD Lion LLC, such finder’s fee to be warrants to purchase 55,000 unregistered shares of common stock of the Company at an exercise price of $0.01 per share, exercisable at any time on or prior to the fifth anniversary of such closing. An additional finder’s fee may be paid to a second finder if the Company closes on the acquisition of 100% of the ownership interests of CBD Lion LLC.

 

Payment of Brokers’ Fees Related to the Sale of Preferred Stock

 

The Company has committed to pay brokers’ fees in regard to the capital being raised for the Company by such brokers in the Company’s private placement of Preferred Stock, such fee to consist of warrants to purchase unregistered shares of common stock of the Company at an exercise price of $1 per share, exercisable at any time during a five year period; the number of such shares will be calculated as six percent of the aggregate capital raised by such brokers in the private placement of Preferred Stock divided by $1.

 

Issuance of Warrants to Purchase Shares of Common Stock of the Company to Board Members

 

The Company has recently added Thomas W. Hines as a seventh member to the Company’s Board of Directors, and the Company expects to add two more members to the Board of Directors during the second quarter of 2019, which will bring the Company's Board of Directors to a total of nine persons. The Compensation Committee of the Company's Board of Directors may recommend that certain warrants to purchase shares of common stock of the Company should be issued to Mr. Hines and to such two additional new Board members, as inducement to them to serve on the Company’s Board of Directors.

Note 8 - Subsequent Events
3 Months Ended
Mar. 31, 2019
Subsequent Events [Abstract]  
Note 8 - Subsequent Events

NOTE 8 – SUBSEQUENT EVENTS

 

Signing of Letter of Intent to Acquire 100% of the Ownership Interests of CBD Lion LLC

 

Please refer to the description included in NOTE 1 – DESCRIPTION OF THE BUSINESS OF ACQUIRED SALES CORP.

 

Acceptance of Subscription From Accredited Investor to Purchase Newly Issued Series A Convertible Preferred Stock

 

Between April 1, 2019 and May 13, 2019, the Company accepted subscriptions from accredited investors to purchase 36,250 shares of newly issued Series A Convertible Preferred Stock ("Preferred Stock") for a purchase price of $3,625,000 in cash. These 36,250 shares of Preferred Stock are convertible at the option of the holder into 3,625,000 shares of newly issued common stock of the Company, or $1.00 per share of common stock of the Company. The Company has committed to file a registration statement covering the shares of newly issued common stock of the Company into which the Preferred Stock can be converted (the "Registration Statement"). The Preferred Stock will receive an annual dividend, and will be subject to mandatory conversion, under terms and conditions set forth in the Certificate of Designation of the Preferred Stock.

 

Payment of Independent Contractor Fees and Reimbursement of Expenses

 

On May 3, 2019, WJacobs was paid the $130,000 in independent contractor fees that were owed to him for the period January 2017 through February 2019. He was also reimbursed for all of the expenses owed to him as of May 3, 2019, which totaled $10,270.

Note 2 - Basis of Presentation and Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2019
Policy Text Block [Abstract]  
Basis of Presentation

Basis of Presentation The accompanying financial statements include the accounts and operations of the Company for all periods presented.

Condensed Financial Statements

Condensed Financial Statements – The accompanying financial statements are condensed and do not include all disclosures normally required by generally accepted accounting principles. These statements should be read in conjunction with the annual financial statements included in Form 10-K filed with the U.S. Securities and Exchange Commission on March 13, 2019. In particular, the basis of presentation and significant accounting principles were presented in Note 1 to the annual financial statements. In the opinion of management, all adjustments necessary for a fair presentation have been included in the accompanying unaudited condensed financial statements and consist of only normal recurring adjustments, except as disclosed herein. The results of operations for the three months ended March 31, 2019 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2019.

Use of Estimates

Use of Estimates – The preparation of financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) typically requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management’s estimates and assumptions. In the past, significant estimates included share-based compensation forfeiture rates and the potential outcome of future tax consequences of events that have been recognized for financial reporting purposes. Actual results and outcomes may differ from our estimates and assumptions.

Basic and Diluted Earnings (Loss) Per Common Share

Basic and Diluted Earnings (Loss) Per Common Share – Basic earnings (loss) per common share is determined by dividing earnings (loss) by the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per common share is calculated by dividing earnings (loss) by the weighted-average number of common shares and dilutive common share equivalents outstanding during the period. When dilutive, the incremental potential common shares issuable upon exercise of stock options and warrants are determined by the treasury stock method. The following table summarizes the calculations of basic and diluted earnings (loss) per common share for the three months ended March 31, 2019 and 2018:

 

    For the Three Months Ended
    March 31,
    2019   2018
Net Loss   $ (44,440)     $ (20,068)  
Weighted Average Shares Outstanding   2,405,777      2,369,648   
         
Basic and Diluted Loss per Share   $ (0.02)     $ (0.01)  

 

In addition, there were 29,900 shares of Preferred Stock that can be converted into 3,090,000 shares of common stock of the Company, that were excluded from the computation of diluted earnings (loss) per share because their effect would be anti-dilutive.

 

At March 31, 2019, there were outstanding options to purchase 1,186,132 shares of common stock exercisable at between $0.001 and $3.18 per share, (b) rights to purchase warrants to purchase 2,740,000 shares of common stock exercisable at between $0.01 and $1.85 per share, and (c) financing warrants to purchase 56,250 shares of common stock exercisable at $0.03 per share. As of the date of this report, none of these outstanding options, rights to purchase warrants or financing warrants have been exercised into shares of common stock. However, all of them may be exercised at any time in the sole discretion of the holder except for certain rights to purchase warrants to purchase 1.25 million shares of our commons stock, which are not exercisable until a performance contingency is met. Also outstanding at March 31, 2019 were 29,900 shares of Preferred Stock, convertible into 2,990,000 shares of the Company’s common stock at an exercise price of $1.00 per common stock share pursuant to the Series A Preferred Stock’s voluntary conversion rights. 

 

In comparison, at March 31, 2018, there were 1,358,774 stock options and rights to purchase warrants to purchase 2,700,000 shares of the Company’s common stock outstanding that were excluded from the computation of diluted earnings (loss) per share because their effects would have been anti-dilutive.

Recent Accounting Pronouncements

Recent Accounting Pronouncements – The Company is unaware of any new accounting pronouncements that will impact the Company upon adoption, and the Company has not recently adopted any new accounting standards.

Note 2 - Basis of Presentation and Significant Accounting Policies: Schedule of Earnings Per Share, Basic and Diluted (Tables)
3 Months Ended
Mar. 31, 2019
Table Text Block Supplement [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted

The following table summarizes the calculations of basic and diluted earnings (loss) per common share for the three months ended March 31, 2019 and 2018:

 

    For the Three Months Ended
    March 31,
    2019   2018
Net Loss   $ (44,440)     $ (20,068)  
Weighted Average Shares Outstanding   2,405,777      2,369,648   
         
Basic and Diluted Loss per Share   $ (0.02)     $ (0.01)  
Note 6 - Shareholders' Equity: Schedule of Stock Options and Warrant Activity (Tables)
3 Months Ended
Mar. 31, 2019
Table Text Block Supplement [Abstract]  
Schedule of Stock Options and Warrant Activity

The following is a summary of stock option and warrant activity as of March 31, 2019 and changes during the period then ended:

 

      Weighted-Average Aggregate
    Weighted-Average Remaining Contractual Intrinsic
  Shares Exercise Price (a) Term (Years) Value
Exercisable Options, Rights to Purchase Warrants to Purchase Common Stock and Financing Warrants Outstanding, December 31, 2018 2,923,632 $ 0.87    4.93    $ 2,410,100   
Financing Warrants Issued During the Period 18,750      
Rights to Purchase Warrants to Purchase Shares of Common Stock Exercised During Period (210,000)      
Exercisable Options, Rights to Purchase Warrants to Purchase Common Stock and Financing Warrants Outstanding, March 31, 2019 2,732,382 $ 0.93    4.20    $ 2,176,550   
Outstanding Options, Rights to Purchase Warrants to Purchase Common Stock and Financing Warrants, March 31, 2019 3,982,382 $ 1.22    4.65    $ 2,176,550   
Note 1 - Description Of The Business Of Acquired Sales Corp. (Details) - USD ($)
1 Months Ended 3 Months Ended
May 08, 2019
May 13, 2019
Apr. 30, 2019
May 13, 2019
Mar. 31, 2019
Number of preffered stock converted into common stock         29,900
Number of common stock converted         2,990,000
Conversion price         $ 1.00
Subsequent Event          
Cash on hand   $ 4,379,077   $ 4,379,077  
Subsequent Event | accredited investors          
Stock puchase for cash, Shares   36,250   66,150  
Stock puchase for cash   $ 3,625,000   $ 6,615,000  
Number of preffered stock converted into common stock   36,250   66,150  
Number of common stock converted   3,625,000   6,615,000  
Conversion price   $ 1.00   $ 1.00  
Acquisition Process description       The Company is likely to structure future acquisitions as a purchase of 19.99% or less, or 50.01% or more, of a target company’s equity ownership interest, or as a so-called tax-free reorganization.  
CBD Lion          
Ownership interests         100.00%
CBD Lion | Subsequent Event          
Ownership interests 100.00%        
Purchse price $ 2,000,000        
Stock Consideration 5,000,000        
Repayment of related party debt 462,430        
Loan $ 300,000        
Letter of Intent description The Letter of Intent will terminate if (i) no audit of Lion satisfactory to the Company has been delivered by August 31, 2019; the Company fails to raise $4 million by September 30, 2019; or (iii) the proposed Transaction has not closed by October 31, 2019.        
Ablis | Subsequent Event          
Ownership interests     4.99%    
Purchse price     $ 399,200    
Additional Ownership interests purchased     15.00%    
Total ownership percentage     19.99%    
Payemnt for aadtional equity     $ 1,200,000    
Bendistillery | Subsequent Event          
Ownership interests     4.99%    
Purchse price     $ 149,700    
Total ownership percentage     19.99%    
Payemnt for aadtional equity     $ 4,050,000    
Bend Spirits | Subsequent Event          
Ownership interests     4.99%    
Purchse price     $ 1,347,300    
Total ownership percentage     19.99%    
Payemnt for aadtional equity     $ 450,000    
Note 2 - Basis of Presentation and Significant Accounting Policies: Basic and Diluted Per Share (Details) - $ / shares
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Number of preffered stock converted into common stock 29,900  
Number of common stock converted 2,990,000  
Conversion price $ 1.00  
Stock Option    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1,186,132 1,358,774
Warrant    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2,740,000 2,700,000
Financing Warrant    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 56,250  
Note 2 - Basis of Presentation and Significant Accounting Policies: Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Text Block [Abstract]    
Net Loss $ (44,440) $ (20,068)
Weighted Average Shares Outstanding 2,405,777 2,369,648
Basic and Diluted Loss per Share $ (0.02) $ (0.01)
Note 3 - Risks and Uncertainties (Details) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Text Block [Abstract]      
Accumulated deficit $ (14,068,681)   $ (14,005,689)
Net Loss $ (44,440) $ (20,068)  
Note 4 - Notes Receivable (Details) - USD ($)
1 Months Ended 7 Months Ended 12 Months Ended
Sep. 01, 2015
Jul. 31, 2015
Jul. 31, 2016
Dec. 31, 2015
Dec. 31, 2016
Jul. 14, 2015
Secured Promissory Note | William Noyes Webster Foundation Inc            
Debt Instrument, Face Amount           $ 1,500,000
Note receivable payment   $ 602,500 $ 135,350      
Advances   600,000        
Note Receivable         $ 737,850  
Debt Instrument, Interest Rate, Stated Percentage         12.50%  
Bad debt expense $ 737,850          
Secured Promissory Note | One-Seven LLC            
Note receivable payment       $ 25,000    
Debt Instrument, Description       In consideration of such $50,000 loan to One-Seven, One-Seven and Stukel agreed that if One-Seven is successful in securing additional funding, then Stukel and One-Seven are obligated to use good faith efforts to work with Gerard M. Jacobs and the Company, as a team and not as a partnership, joint venture or other entity, in order to explore and hopefully close transactions pursuant to which: (a) One-Seven may provide debt, convertible debt and/or equity to the Company, all on mutually acceptable terms and conditions; (b) One-Seven may provide debt, convertible debt and/or equity to business entities that may be wholly or partly purchased by, or merged into, the Company, all on mutually acceptable terms and conditions; and (c) Stukel may participate in the management of the Company and obtain a salary and a package of stock options and/or warrants to purchase shares of common stock of the Company, all on mutually acceptable terms and conditions.    
Interest receivable {1} | William Noyes Webster Foundation Inc            
Bad debt expense $ 97,427          
Payment To Consultant | Secured Promissory Note | William Noyes Webster Foundation Inc            
Advances   $ 2,500        
Unfunded Portion of Note | Secured Promissory Note | William Noyes Webster Foundation Inc            
Debt Instrument, Face Amount           $ 897,500
Note 5 - Amounts Owed To Related Parties (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 15, 2019
Mar. 13, 2019
Jul. 13, 2018
Feb. 06, 2019
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Jun. 21, 2016
Repayment of note payable         $ 45,562 $ 0      
Payment of contractor fees         130,000        
Reimbursement of expenses         10,270        
Interest payable         0   $ 1,381    
Eide Bailly LLP                  
Repayment of debt $ 61,500                
Joshua A. Bloom                  
Repayment of borrowings   $ 21,540              
Gerard M. Jacobs                  
Due to Other Related Parties, Current                 $ 4,000
Due to Related Parties, Current         3,555     $ 24,583  
Long-term Debt, Gross       $ 14,772          
Repayment of borrowings   $ 26,628              
William C. Jacobs                  
Due to Related Parties, Current         136,825   164,417    
Repayment of note payable         4,379,077        
Payment of contractor fees         40,000        
Reimbursement of expenses         4,417        
William C. Jacobs | Independent contractor fees                  
Due to Related Parties, Current         130,000   160,000    
William C. Jacobs | Salary                  
Due to Related Parties, Current         5,000        
William C. Jacobs | Expense reimbursements                  
Due to Related Parties, Current         $ 1,825   $ 4,417    
Warrant 1 | Joshua A. Bloom                  
Warrants issued             25,000    
Warrant 1 | Gerard M. Jacobs                  
Warrants issued       18,750     12,500    
Financing warrants                  
Debt Instrument, Payment Terms     (1) proceeds of the borrowings will be used to pay professional fees owed to our outside auditors, our stock transfer agent, and our securities counsel, and to pay other obligations of AQSP; (2) the borrowings will be evidenced by promissory notes of AQSP, accruing interest at the rate of 15% annually; (3) the notes will be jointly secured by a first lien security interest in all of the assets of AQSP, pursuant to a security agreement signed by AQSP in favor of the lenders, UCC filings in favor of the lenders, and a pledge to the lenders of the note payable by the William Noyes Webster Foundation Inc. to AQSP; (4) the notes shall be due and payable upon demand by the lenders delivered to AQSP; and (5) for each $1,000 loaned by AQSP on these terms, the lender of such $1,000 shall receive warrants to purchase 1,250 shares of common stock of AQSP, at an exercise price of $0.03 per share, exercisable at the discretion of such lender any time on or before July 16, 2023.            
Long-term Debt, Gross             $ 30,791    
Note 6 - Shareholders' Equity (Details) - USD ($)
1 Months Ended 3 Months Ended
Jul. 13, 2018
May 13, 2019
May 13, 2019
Mar. 31, 2019
Dec. 31, 2018
Stock compensation expense       $ 26,773  
Preferred Stock, par or stated value       $ 0.001 $ 0.001
Preferred Stock, shares authorized       10,000,000 10,000,000
Issuance of Preferred Stock description       Each share of Preferred Stock may be converted into 100 shares of common stock. The Preferred Stock pays dividends at the rate of 3% annually. The Preferred Stock dividends are cumulative if the Company does not have the necessary cash to pay the dividend when due. The Preferred Stock dividends shall cease to accrue at such time as the Company’s Common Stock has closed at $3.00 per share or higher for 20 consecutive trading days after the first date that the registration statement is effective, and there have been, on average, at least 25,000 shares traded on each of those 20 consecutive trading days. The Preferred Stock have no voting rights. The holders of the Preferred Stock shall have voluntary conversion rights. Shares of Preferred Stock are subject to mandatory conversion (in the discretion of the Company) at such time as the Company’s common stock has closed at $5.00 per share or higher for 20 consecutive trading days after the first date that the registration statement is effective, and there have been, on average, at least 50,000 shares traded on each of those 20 consecutive trading days  
Number of preffered stock converted into common stock       29,900  
Number of common stock converted       2,990,000  
Conversion price       $ 1.00  
accredited investors | Subsequent Event          
Stock puchase for cash, Shares   36,250 66,150    
Stock puchase for cash   $ 3,625,000 $ 6,615,000    
Number of preffered stock converted into common stock   36,250 66,150    
Number of common stock converted   3,625,000 6,615,000    
Conversion price   $ 1.00 $ 1.00    
James S. Jacobs          
Purchase of warrants       18,750  
WJacobs          
Amount borrowed       $ 14,772  
Financing warrants          
Debt Instrument, Payment Terms (1) proceeds of the borrowings will be used to pay professional fees owed to our outside auditors, our stock transfer agent, and our securities counsel, and to pay other obligations of AQSP; (2) the borrowings will be evidenced by promissory notes of AQSP, accruing interest at the rate of 15% annually; (3) the notes will be jointly secured by a first lien security interest in all of the assets of AQSP, pursuant to a security agreement signed by AQSP in favor of the lenders, UCC filings in favor of the lenders, and a pledge to the lenders of the note payable by the William Noyes Webster Foundation Inc. to AQSP; (4) the notes shall be due and payable upon demand by the lenders delivered to AQSP; and (5) for each $1,000 loaned by AQSP on these terms, the lender of such $1,000 shall receive warrants to purchase 1,250 shares of common stock of AQSP, at an exercise price of $0.03 per share, exercisable at the discretion of such lender any time on or before July 16, 2023.        
Note 6 - Shareholders' Equity: Schedule of Share-based Compensation, Stock Options and Warrant Activity (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2019
Dec. 31, 2018
Text Block [Abstract]    
Exercisable Options, Rights to Purchase Warrants and Financing Warrants Outstanding 2,923,632  
Financing Warrants Issued During Period 18,750  
Rights to Purchase Warrants to Purchase Shares of Common Stock Exercised During Period (210,000)  
Options, Rights to Purchase Warrants and Financing Warrants Outstanding, Ending Balance 2,732,382  
Exercisable Options, Rights to Purchase Warrants and Financing Warrants Outstanding 3,982,382 2,923,632
Exercisable Options, Rights to Purchase Warrants and Financing Warrants, Weighted Average Exercise Price $ 0.87  
Options, Rights to Purchase Warrants and Financing Warrants Outstanding, Weighted Average Exercise Price, Ending Balance 0.93  
Exercisable Options, Rights to Purchase Warrants and Financing Warrants, Weighted Average Exercise Price $ 1.22 $ 0.87
Options, Rights to Purchase Warrants and Financing Warrants Outstanding, Weighted Average Remaining Term 4 years 2 months 12 days 4 years 11 months 4 days
Options, Outstanding, Weighted Average Remaining Term 4 years 7 months 24 days  
Exercisable Options, Rights to Purchase Warrants and Financing Warrants, Intrinsic Value $ 2,410,100  
Options, Outstanding, Intrinsic Value, Ending Balance 2,176,550  
Exercisable Options, Rights to Purchase Warrants and Financing Warrants, Intrinsic Value $ 2,176,550 $ 2,410,100
Note 7 - Contingent Contractual Obligations and Commercial Commitments (Details)
3 Months Ended
Mar. 31, 2019
$ / shares
shares
Commitments description The amount of the authorized compensation is 10% of the consideration paid by the Company to acquire equity ownership interests in target companies.
Payment of Brokers’ Fees Descriptiopn The Company has committed to pay brokers’ fees in regard to the capital being raised for the Company by such brokers in the Company’s private placement of Preferred Stock, such fee to consist of warrants to purchase unregistered shares of common stock of the Company at an exercise price of $1 per share, exercisable at any time during a five year period; the number of such shares will be calculated as six percent of the aggregate capital raised by such brokers in the private placement of Preferred Stock divided by $1.
CBD Lion  
Percntage of common stock purchase 1.00
Warrants to purchase 55,000
Exercise price | $ / shares $ 0.01
Ownership interests 100.00%
Ablis  
Percntage of common stock purchase 0.0499
Warrants to purchase 14,042
Additional Percntage of common stock purchase 15.00%
Additional Warrants to purchase 2,814
Maximum warrants issued 42,210
Exercise price | $ / shares $ 1.00
Warrants expire date Apr. 30, 2024
Note 8 - Subsequent Events (Details) - USD ($)
1 Months Ended 3 Months Ended
May 13, 2019
May 13, 2019
Mar. 31, 2019
Number of preffered stock converted into common stock     29,900
Number of common stock converted     2,990,000
Conversion price     $ 1.00
Payment of contractor fees     $ 130,000
Reimbursement of expenses     $ 10,270
Subsequent Event | accredited investors      
Stock puchase for cash, Shares 36,250 66,150  
Stock puchase for cash $ 3,625,000 $ 6,615,000  
Number of preffered stock converted into common stock 36,250 66,150  
Number of common stock converted 3,625,000 6,615,000  
Conversion price $ 1.00 $ 1.00